The Inquirer & Mirror, March 9, 2026: This letter to the editor, also sent to the Nantucket Board of Health, from NCHR president Diana Zuckerman outlines human health and environmental contamination concerns related to proposed artificial turf at Nantucket High School. Zuckerman urges officials to rely on independent science and prioritize natural grass to protect public health and the island’s environment.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
As controversial decisions mount, FDA shuns public advisory meetings
STAT News, March 9, 2026: FDA is holding very few Advisory Committee meetings in 2025-26 compared to previous years. FDA says they want to avoid undue industry influence. But these meetings also provide opportunities for a diversity of opinion says NCHR’s Diana Zuckerman, who points out that FDA is avoiding meetings with experts who disagree with what the agency has already decided to do.
Read More »Two AstraZeneca Drugs To Be Scrutinized in First FDA Cancer Advisory Panel in 9 Months
BioSpace, March 9, 2026: In April 2026 FDA will hold its first Advisory Committee meeting on cancer drugs in 9 months — the first one in FY 2026. It will discuss 2 AstraZeneca applications, one for a new drug for HR-positive HER2-negative breast cancer and the other for Truqap to treat metastatic hormone-sensitive prostate cancer.
Read More »Prasad Out At FDA, Turning Critics’ Focus Back To Makary
Inside Health Policy, March 6, 2026: FDA’s biologics chief Vinay Prasad is leaving FDA for the second time. This time his rejection of Uniqure and other rare disease treatments angered industry and some rare disease patients, and Members of Congress. But NCHR’s Zuckerman says Prasad’s focus on evidence strengthened FDA and will be missed.
Read More »Divisive F.D.A. Vaccine Regulator Is Resigning
New York Times, March 6, 2026: FDA’s biologics chief Vinay Prasad is resigning, leaving FDA for the second time. This time his rejection of rare disease treatments angered industry, some rare disease patients, and Members of Congress. But NCHR’s Diana Zuckerman says Prasad’s focus on evidence was welcomed by researchers and advocates who were concerned about FDA’s approval of ineffective treatments.
Read More »